Theivanthiran, B., Evans, K., DeVito, N., Plebanek, M., Sturdivant, M., Holtzhausen, A., … Hanks, B. (2019). A tumor PD-L1-NLRP3 inflammasome signaling axis drives adaptive resistance to anti-PD-1 immunotherapy. In JOURNAL FOR IMMUNOTHERAPY OF CANCER (Vol. 7). BMC.

Theivanthiran, Balamayooran, Kathy Evans, Nicholas DeVito, Michael Plebanek, Michael Sturdivant, Alisha Holtzhausen, Luke Wachsmuth, et al. “A tumor PD-L1-NLRP3 inflammasome signaling axis drives adaptive resistance to anti-PD-1 immunotherapy.” In JOURNAL FOR IMMUNOTHERAPY OF CANCER, Vol. 7. BMC, 2019.

Theivanthiran B, Evans K, DeVito N, Plebanek M, Sturdivant M, Holtzhausen A, et al. A tumor PD-L1-NLRP3 inflammasome signaling axis drives adaptive resistance to anti-PD-1 immunotherapy. In: JOURNAL FOR IMMUNOTHERAPY OF CANCER. BMC; 2019.

Theivanthiran, Balamayooran, et al. “A tumor PD-L1-NLRP3 inflammasome signaling axis drives adaptive resistance to anti-PD-1 immunotherapy.” JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 7, BMC, 2019.

Theivanthiran B, Evans K, DeVito N, Plebanek M, Sturdivant M, Holtzhausen A, Wachsmuth L, Salama A, Kang Y, Hsu D, Balko J, Johnson D, Starr M, Nixon A, Hanks B. A tumor PD-L1-NLRP3 inflammasome signaling axis drives adaptive resistance to anti-PD-1 immunotherapy. JOURNAL FOR IMMUNOTHERAPY OF CANCER. BMC; 2019.